A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR

Hillard M. Lazarus, Mei Jie Zhang, Jeanette Carreras, Brandon Hayes-Lattin, Asli Selmin Ataergin, Jacob D. Bitran, Brian J. Bolwell, César O. Freytes, Robert Peter Gale, Steven C. Goldstein, Gregory A. Hale, David J. Inwards, Thomas R. Klumpp, David I. Marks, Richard Maziarz, Philip L. McCarthy, Santiago Pavlovsky, J. Douglas Rizzo, Thomas C. Shea, Harry C. SchoutenShimon Slavin, Jane N. Winter, Koen van Besien, Julie M. Vose, Parameswaran N. Hari

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

We compared outcomes of 916 diffuse large B cell lymphoma (DLBCL) patients aged ≥18 years undergoing first autologous (n = 837) or myeloablative (MA) allogeneic hematopoietic cell transplant (HCT) (n = 79) between 1995 and 2003 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Median follow-up was 81 months for allogeneic HCT versus 60 months for autologous HCT. Allogeneic HCT recipients were more likely to have high-risk disease features including higher stage, more prior chemotherapy regimens, and resistant disease. Allogeneic HCT was associated with a higher 1 year treatment-related mortality (TRM) (relative risk [RR] 4.88, 95% confidence interval [CI], 3.21-7.40, P <.001), treatment failure (RR 2.06, 95% CI, 1.54-2.75, P <.001), and mortality (RR 2.75, 95% CI, 2.03-3.72, P <.001). Risk of disease progression was similar in the 2 groups (RR 1.12, 95% CI, 0.73-1.72, P = .59). In fact, for 1-year survivors, no significant differences were observed for TRM, progression, progression-free (PFS) or overall survival (OS). Increased risks of TRM and mortality were associated with older age (>50 years), lower performance score, chemoresistance, and earlier year of transplant. In a cohort of mainly high-risk DLBCL patients, upfront MA allogeneic HCT, although associated with increased early mortality, was associated with a similar risk of disease progression compared to lower risk patients receiving autologous HCT.

Original languageEnglish (US)
Pages (from-to)35-45
Number of pages11
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Autologous Transplantation
Siblings
Lymphoma
Bone Marrow
Transplants
Research
Lymphoma, Large B-Cell, Diffuse
Mortality
Disease Progression
Confidence Intervals
Drug Therapy

Keywords

  • Allogeneic transplantation
  • Hodgkin lymphoma
  • Unrelated

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma : A Report from the CIBMTR. / Lazarus, Hillard M.; Zhang, Mei Jie; Carreras, Jeanette; Hayes-Lattin, Brandon; Ataergin, Asli Selmin; Bitran, Jacob D.; Bolwell, Brian J.; Freytes, César O.; Gale, Robert Peter; Goldstein, Steven C.; Hale, Gregory A.; Inwards, David J.; Klumpp, Thomas R.; Marks, David I.; Maziarz, Richard; McCarthy, Philip L.; Pavlovsky, Santiago; Rizzo, J. Douglas; Shea, Thomas C.; Schouten, Harry C.; Slavin, Shimon; Winter, Jane N.; van Besien, Koen; Vose, Julie M.; Hari, Parameswaran N.

In: Biology of Blood and Marrow Transplantation, Vol. 16, No. 1, 01.2010, p. 35-45.

Research output: Contribution to journalArticle

Lazarus, HM, Zhang, MJ, Carreras, J, Hayes-Lattin, B, Ataergin, AS, Bitran, JD, Bolwell, BJ, Freytes, CO, Gale, RP, Goldstein, SC, Hale, GA, Inwards, DJ, Klumpp, TR, Marks, DI, Maziarz, R, McCarthy, PL, Pavlovsky, S, Rizzo, JD, Shea, TC, Schouten, HC, Slavin, S, Winter, JN, van Besien, K, Vose, JM & Hari, PN 2010, 'A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR', Biology of Blood and Marrow Transplantation, vol. 16, no. 1, pp. 35-45. https://doi.org/10.1016/j.bbmt.2009.08.011
Lazarus, Hillard M. ; Zhang, Mei Jie ; Carreras, Jeanette ; Hayes-Lattin, Brandon ; Ataergin, Asli Selmin ; Bitran, Jacob D. ; Bolwell, Brian J. ; Freytes, César O. ; Gale, Robert Peter ; Goldstein, Steven C. ; Hale, Gregory A. ; Inwards, David J. ; Klumpp, Thomas R. ; Marks, David I. ; Maziarz, Richard ; McCarthy, Philip L. ; Pavlovsky, Santiago ; Rizzo, J. Douglas ; Shea, Thomas C. ; Schouten, Harry C. ; Slavin, Shimon ; Winter, Jane N. ; van Besien, Koen ; Vose, Julie M. ; Hari, Parameswaran N. / A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma : A Report from the CIBMTR. In: Biology of Blood and Marrow Transplantation. 2010 ; Vol. 16, No. 1. pp. 35-45.
@article{71ce0f4e6bb04b86824f970691154473,
title = "A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR",
abstract = "We compared outcomes of 916 diffuse large B cell lymphoma (DLBCL) patients aged ≥18 years undergoing first autologous (n = 837) or myeloablative (MA) allogeneic hematopoietic cell transplant (HCT) (n = 79) between 1995 and 2003 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Median follow-up was 81 months for allogeneic HCT versus 60 months for autologous HCT. Allogeneic HCT recipients were more likely to have high-risk disease features including higher stage, more prior chemotherapy regimens, and resistant disease. Allogeneic HCT was associated with a higher 1 year treatment-related mortality (TRM) (relative risk [RR] 4.88, 95{\%} confidence interval [CI], 3.21-7.40, P <.001), treatment failure (RR 2.06, 95{\%} CI, 1.54-2.75, P <.001), and mortality (RR 2.75, 95{\%} CI, 2.03-3.72, P <.001). Risk of disease progression was similar in the 2 groups (RR 1.12, 95{\%} CI, 0.73-1.72, P = .59). In fact, for 1-year survivors, no significant differences were observed for TRM, progression, progression-free (PFS) or overall survival (OS). Increased risks of TRM and mortality were associated with older age (>50 years), lower performance score, chemoresistance, and earlier year of transplant. In a cohort of mainly high-risk DLBCL patients, upfront MA allogeneic HCT, although associated with increased early mortality, was associated with a similar risk of disease progression compared to lower risk patients receiving autologous HCT.",
keywords = "Allogeneic transplantation, Hodgkin lymphoma, Unrelated",
author = "Lazarus, {Hillard M.} and Zhang, {Mei Jie} and Jeanette Carreras and Brandon Hayes-Lattin and Ataergin, {Asli Selmin} and Bitran, {Jacob D.} and Bolwell, {Brian J.} and Freytes, {C{\'e}sar O.} and Gale, {Robert Peter} and Goldstein, {Steven C.} and Hale, {Gregory A.} and Inwards, {David J.} and Klumpp, {Thomas R.} and Marks, {David I.} and Richard Maziarz and McCarthy, {Philip L.} and Santiago Pavlovsky and Rizzo, {J. Douglas} and Shea, {Thomas C.} and Schouten, {Harry C.} and Shimon Slavin and Winter, {Jane N.} and {van Besien}, Koen and Vose, {Julie M.} and Hari, {Parameswaran N.}",
year = "2010",
month = "1",
doi = "10.1016/j.bbmt.2009.08.011",
language = "English (US)",
volume = "16",
pages = "35--45",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma

T2 - A Report from the CIBMTR

AU - Lazarus, Hillard M.

AU - Zhang, Mei Jie

AU - Carreras, Jeanette

AU - Hayes-Lattin, Brandon

AU - Ataergin, Asli Selmin

AU - Bitran, Jacob D.

AU - Bolwell, Brian J.

AU - Freytes, César O.

AU - Gale, Robert Peter

AU - Goldstein, Steven C.

AU - Hale, Gregory A.

AU - Inwards, David J.

AU - Klumpp, Thomas R.

AU - Marks, David I.

AU - Maziarz, Richard

AU - McCarthy, Philip L.

AU - Pavlovsky, Santiago

AU - Rizzo, J. Douglas

AU - Shea, Thomas C.

AU - Schouten, Harry C.

AU - Slavin, Shimon

AU - Winter, Jane N.

AU - van Besien, Koen

AU - Vose, Julie M.

AU - Hari, Parameswaran N.

PY - 2010/1

Y1 - 2010/1

N2 - We compared outcomes of 916 diffuse large B cell lymphoma (DLBCL) patients aged ≥18 years undergoing first autologous (n = 837) or myeloablative (MA) allogeneic hematopoietic cell transplant (HCT) (n = 79) between 1995 and 2003 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Median follow-up was 81 months for allogeneic HCT versus 60 months for autologous HCT. Allogeneic HCT recipients were more likely to have high-risk disease features including higher stage, more prior chemotherapy regimens, and resistant disease. Allogeneic HCT was associated with a higher 1 year treatment-related mortality (TRM) (relative risk [RR] 4.88, 95% confidence interval [CI], 3.21-7.40, P <.001), treatment failure (RR 2.06, 95% CI, 1.54-2.75, P <.001), and mortality (RR 2.75, 95% CI, 2.03-3.72, P <.001). Risk of disease progression was similar in the 2 groups (RR 1.12, 95% CI, 0.73-1.72, P = .59). In fact, for 1-year survivors, no significant differences were observed for TRM, progression, progression-free (PFS) or overall survival (OS). Increased risks of TRM and mortality were associated with older age (>50 years), lower performance score, chemoresistance, and earlier year of transplant. In a cohort of mainly high-risk DLBCL patients, upfront MA allogeneic HCT, although associated with increased early mortality, was associated with a similar risk of disease progression compared to lower risk patients receiving autologous HCT.

AB - We compared outcomes of 916 diffuse large B cell lymphoma (DLBCL) patients aged ≥18 years undergoing first autologous (n = 837) or myeloablative (MA) allogeneic hematopoietic cell transplant (HCT) (n = 79) between 1995 and 2003 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Median follow-up was 81 months for allogeneic HCT versus 60 months for autologous HCT. Allogeneic HCT recipients were more likely to have high-risk disease features including higher stage, more prior chemotherapy regimens, and resistant disease. Allogeneic HCT was associated with a higher 1 year treatment-related mortality (TRM) (relative risk [RR] 4.88, 95% confidence interval [CI], 3.21-7.40, P <.001), treatment failure (RR 2.06, 95% CI, 1.54-2.75, P <.001), and mortality (RR 2.75, 95% CI, 2.03-3.72, P <.001). Risk of disease progression was similar in the 2 groups (RR 1.12, 95% CI, 0.73-1.72, P = .59). In fact, for 1-year survivors, no significant differences were observed for TRM, progression, progression-free (PFS) or overall survival (OS). Increased risks of TRM and mortality were associated with older age (>50 years), lower performance score, chemoresistance, and earlier year of transplant. In a cohort of mainly high-risk DLBCL patients, upfront MA allogeneic HCT, although associated with increased early mortality, was associated with a similar risk of disease progression compared to lower risk patients receiving autologous HCT.

KW - Allogeneic transplantation

KW - Hodgkin lymphoma

KW - Unrelated

UR - http://www.scopus.com/inward/record.url?scp=72649090031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72649090031&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.08.011

DO - 10.1016/j.bbmt.2009.08.011

M3 - Article

C2 - 20053330

AN - SCOPUS:72649090031

VL - 16

SP - 35

EP - 45

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1

ER -